Suggested remit: To appraise the clinical and cost effectiveness of ticagrelor within its marketing authorisation for preventing stroke after previous acute ischaemic stroke or high-risk transient ischaemic attack.
Following on from information provided to NICE by the company in July 2022, the appraisal of Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
ID number 2689

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 July 2023 Discontinued. Following on from information provided to NICE by the company in July 2022, the appraisal of Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 July 2022 Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
05 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of ticagrelor within its marketing authorisation for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
03 September 2020 In progress. Topic is in progress
03 September 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of ticagrelor within its marketing authorisation for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2021. These timings are based on a three month delay request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
11 June 2020 - 09 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual